



Small but heading for a big time

Nanobiotix strengthens its Supervisory Board for the next stage of its development

Anne-Marie GRAFFIN and Enno SPILLNER join the Supervisory Board

Paris, France, 16 January, 2014 – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the entry of Anne-Marie GRAFFIN and Enno SPILLNER to the Supervisory Board of the Company.

After a year rich in positive news for Nanobiotix in 2013, the next few years will be key to the Company's future development. In the short term, **there are two strategic priorities**: firstly, **to continue the development of the three NanoXray products** (NBTXR3, NBTX-IV and NBTX-TOPO), with a planned potential market authorization of lead product NBTXR3 in 2017, and secondly, **to expand the Company's ambitious partnership policy** to focus on the US to effectively address this significant market. Longer term, the ultimate ambition is for the NanoXray pipeline to address all types of cancer treated with radiotherapy.

To support the next steps in the development of Nanobiotix, the Company has completed its Supervisory Board, bringing in people who will provide Nanobiotix and its shareholders recognized expertise in Finance, Capital markets, Oncology, International Market Access for healthcare products and Business Development.

After a varied career of over 20 years in the pharmaceutical industry, Anne-Marie GRAFFIN has both expertise in developing market access strategies and in driving biotechnology companies' growth. She has been a consultant to the pharmaceutical industry since 2011. Before then, she worked for five years at ROC as international brand manager. Then, she worked for 12 years at Sanofi Pasteur MSD, where she was Director of Marketing – Adult Vaccines, Europe. She also had corporate responsibilities at the company as Executive Director Business Management and then Vice-President for Europe. Anne-Marie GRAFFIN has been coopted as a Supervisory Board member following the resignation of Jérôme SNOLLAERTS in November 2013.

Enno SPILLNER has more than 14 years' experience in the life science industry and is now CEO and CFO of the listed German biotech company, 4SC AG, which is developing innovative targeted drugs for the treatment of cancer and autoimmune diseases. Enno SPILLNER has extensive experience in finance, capital market transactions and in strategic corporate development. Prior to 4SC, he was Head of Finance and Managing Partner of the German regional biotech venture fund, BioM AG. He was also Managing Director of two portfolio companies, ACTIPAC Biosystems GmbH and Munich innovative Biomaterials GmbH. Enno SPILLNER joins the Supervisory Board as observer.

The arrival of Anne-Marie GRAFFIN and Enno SPILLNER, completes the composition of Nanobiotix's Supervisory Board and sets it up with the best support for its future development. *"I'm delighted to announce the appointments of Anne-Marie GRAFFIN and Enno SPILLNER, both experts in market access strategy, in Finance and in the development of innovative biotech companies. They have considerable understanding of the international markets, and therefore they will both be valuable*

partners in achieving the ambitious roadmap that has been planned for Nanobiotix's future. Their skills effectively complement those of the other members of the Supervisory Board and we look forward to working with them," said Laurent Condomine, Chairman of the Supervisory Board. "I would also like to thank Jérôme SNOLLAERTS for the precious advice he has made over the last years of service."

It will be proposed to the next General Assembly to ratify the nomination of Anne-Marie GRAFFIN in accordance with applicable French law and to appoint Enno SPILLNER as a full Board member.

•••

For the record, the Supervisory Board is currently composed of three members:

Laurent CONDOMINE, Chairman of the Supervisory Board of Nanobiotix

Laurent CONDOMINE has an experience of over thirty years in the Pharmaceutical Industry. He used to be Vice-President of Business Development at AstraZeneca, where he was responsible for group strategy and mergers and acquisitions. Previously, he held a similar position in the ICI group and was notably involved in the group spin-off and the creation of Zeneca in 1993. He then held the same position at Zeneca, where he played a key role in the company's merger with Astra in 1998. In 2007, he became an important member of the team in charge of AstraZeneca's acquisition of MedImmune. The pharmaceutical industry has always been at the heart of his career, as he joined ICI-Pharma in 1973, where he being promoted to Chairman and Chief Executive in 1984. In 1992, he went to work at ICI's head office in London.

Christophe DOUAT

Christophe DOUAT is currently Chairman of Medincell, a pharmaceutical company that specializes in drug administration technologies, and President of Great North, dedicated to advise companies with disruptive technology. Christophe was a member of the Supervisory Board of Nanobiotix from 2006 to 2009 when he was lead investor, and was appointed again member of the Board in 2011. Christophe joined the venture capital company Matignon Technologies in 2001, where he has invested in a broad range of companies and founded Matignon Technologies II, one of Europe's largest funds specialized in Medtech.

Alain HERRERA

Alain HERRERA, MD joins Nanobiotix Supervisory Board with more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. Before setting up his own oncology consultancy, he headed the Oncology business at Sanofi-Aventis for ten years, where he was Vice President for the Global Oncology Business Strategy and Development (2007-2008) and Head of the Global Oncology Franchise (1998-2007). He contributed to the worldwide registration of Oxaliplatin (Eloxatin®) and Rasburicase (Fasturtec®/Elitek®), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere®). His previous responsibilities within the pharmaceutical industry included the roles of Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc). In addition to these roles, since 1991, Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital.

About NANOBIOTIX - www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please contact:

Nanobiotix

Sarah Gaubert

*Head of Communication
and Public Affairs*

+33 (0)1 40 26 07 55

contact@nanobiotix.com

NewCap.

*Financial communication
and investors relations*

Louis-Victor Delouvrier / Emmanuel Huynh

+33 (0)1 44 71 98 53

lvdelouvrier@newcap.fr

Yucatan

Media relations (France)

Annie-Florence Loyer / Nadège Le Lezec

+33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59

afloyer@yucatan.fr

College Hill

Media relations (Outside France)

Melanie Toyne Sewell / Donia Al Saffar

+44 (0) 207 457 2020

nanobiotix@collegehill.com



Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2012 financial annual report of Nanobiotix (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.